Professor, Department of Medicine Harvard Medical School Director Gynecologic Medical Oncology
Oncology
Dr. Michael J. Birrer, MD
|
|
Give Review
Michael Birrer works in the field of Oncology. He studied medicine at Albert Einstein College of Medicine of Yeshiva University. He over the years received 4 awards: "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer" and "Super Doctor". Michael J. Birrer is a published doctor and has 99 publications published. The lastest was: 'Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus.
- Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
- Creation of a human Secretome: Novel Composite Library of Human Secreted Proteins: Validation using Ovarian Cancer Gene Expression Data and Virtual Secretome Array.
- Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian Cancer mouse models.
- Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian Cancer.
- Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.
- A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian Cancer.
- Rethinking ovarian Cancer II: reducing mortality from high-grade serous ovarian Cancer.
- Exploring alternative ovarian Cancer biomarkers using innovative nanotechnology strategies.
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
- Molecular subtypes of high-grade serous ovarian Cancer: the holy grail?
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian Cancer: a randomised phase 2 study.
- Advances in the diagnosis and treatment of Uterine sarcomas.
- Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples.
- Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer.
- Better Therapeutic Trials in Ovarian Cancer.
- Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer.
- Ascites Analysis by a microfluidic chip allows tumor-cell profiling.
- Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era.
- Clear cell Cancer of the ovary.
- FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.
- Identification of LMX1B as a novel oncogene in human ovarian Cancer.
- Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian Cancer.
- TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment.
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ova...
- BRCA1 expression and improved survival in ovarian Cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
- Low-grade and high-grade serous Mullerian carcinoma: review and Analysis of publicly available gene expression profiles.
- Inherited variants in regulatory T cell genes and outcome of ovarian Cancer.
- Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer.
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
- Prognostically relevant gene signatures of high-grade serous Ovarian carcinoma.
- Uterine papillary serous Cancer: A review of the literature.
- Clear cell carcinoma of the ovary: A review of the literature.
- Common variation in Nemo-like kinase (NLK) is associated with risk of ovarian Cancer.
- ALDH1A1 is a novel EZH2 target gene in epithelial ovarian Cancer identified by genome-wide approaches.
- Reclassification of serous Ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study.
- Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homogeneity in serous Ovarian carcinoma.
- Tissue-based immune monitoring I: Tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.
- Wnt5a Suppresses Epithelial Ovarian Cancer by Promoting Cellular Senescence.
- CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer.
- MicroRNA Processing and Binding Site Polymorphisms are not Replicated in the Ovarian Cancer Association Consortium.
- The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer.
- Nuclear P27 expression in benign, borderline (LMP) and invasive Tumors of the ovary and its association with prognosis: A gynecologic oncology group study.
- LIN28B polymorphisms influence susceptibility to epithelial ovarian Cancer.
- The role of KRAS rs61764370 in invasive epithelial ovarian Cancer: implications for clinical testing.
- Identification of novel therapeutic targets in microdissected clear cell ovarian Cancers.
- Inhibition of hedgehog signaling antagonizes serous ovarian Cancer growth in a primary xenograft model.
- Activity of sorafenib in recurrent ovarian Cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
- The origin of ovarian Cancer—is it getting clearer?
- Up-regulation of stromal versican expression in advanced stage serous ovarian Cancer.
- Regulation of tumor angiogenesis by EZH2.
- CD157 in Ovarian carcinoma: how does it help us?
- Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian Cancer.
- Translational research in the Gynecologic Oncology Group: evaluation of ovarian Cancer markers, profiles, and novel therapies.
- Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian Cancer.
- Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women w...
- FGFR2 mutations are rare across histologic subtypes of ovarian Cancer.
- NIH and NCI support for development of novel therapeutics in gynecologic Cancer: a user's guide.
- A polymorphism in the GALNT2 gene and ovarian Cancer risk in four population based case-control studies.
- A gene signature predictive for outcome in advanced ovarian Cancer identifies a survival factor: microfibril-associated glycoprotein 2.
- Ovarian Cancer: markers of response.
- Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian Cancers: a Gynecologic Oncol...
- Matrilysin-1 mediates bronchiolization of alveoli, a potential premalignant change in lung Cancer.
- NORE1A tumor suppressor candidate modulates p21CIP1 via p53.
- Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian Cancers: a Gyne...
- Validation of serum biomarkers for detection of early-stage ovarian Cancer.
- A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal Cancer.
- Calcineurin activates cytoglobin transcription in hypoxic myocytes.
- The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical Cancer and are critical for Cancer cell survival and proliferation.
- Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women.
- Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.
- Novel therapeutic targets.
- Dicer, Drosha, and outcomes in patients with ovarian Cancer.
- Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian Cancer.
- Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian Cancer cell lines.
- A gene signature predicting for survival in suboptimally debulked patients with ovarian Cancer.
- Highlights from the 2008 Annual Meeting of the American Association for Cancer Research.
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian Cancer.
- Overexpression of CEACAM6 in borderline and invasive mucinous Ovarian neoplasms.
- Early events in the pathogenesis of epithelial ovarian Cancer.
- Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activity.
- Classification of ovarian Cancer: a genomic analysis.
- Reactive oxygen species mediated apoptosis of esophageal Cancer cells induced by marine triprenyl toluquinones and toluhydroquinones.
- Whole genome oligonucleotide-based array comparative genomic hybridization Analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage ser...
- Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive Ovarian carcinoma.
- Biomarker discovery in epithelial ovarian Cancer by genomic approaches.
- The future of phase II trials.
- Biomarkers and clinical trial design.
- Summary and discussion of session recommendations.
- Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian Cancer.
- Ovarian Cancer: not a borderline issue!
- Roles of KLF6 and KLF6-SV1 in ovarian Cancer progression and intraperitoneal dissemination.
- Expression profiling of mucinous Tumors of the ovary identifies genes of clinicopathologic importance.
- Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts.
- Expression profiling of serous low malignant potential, low-grade, and high-grade Tumors of the ovary.
- Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray Analyses.
- Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial Cancer.
- Gene expression profiles associated with response to chemotherapy in epithelial ovarian Cancers.
Schools
Albert Einstein College of Medicine of Yeshiva University
Massachusetts General Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Super Doctor
Education
-
National Institutes of Health Clinical Center -
Massachusetts General Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
Brigham and Women's Hospital -
Newton-Wellesley Hospital -
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1164643714 | |
| NPPES Provider LastName | BIRRER | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 56.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164643714 |
| Last Name Of The Provider | BIRRER |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Richard T. Penson, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jason E. Faris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Otto Metzger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suniti N. Nimbkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Lathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip C. Amrein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca A. Miksad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey R. Oxnard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael R. Cassidy, MD
This Doctor is OpenDoctor Recommended.
|